BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McIntyre RS, Lee Y, Mansur RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr 2015;20 Suppl 1:20-30; quiz 31. [PMID: 26683526 DOI: 10.1017/S1092852915000826] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Shin C, Pae CU, Kwak KP, Jeon SW, Jeong HG, Kim JW, Lee YJ, Patkar AA, Han C. Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder. Clin Psychopharmacol Neurosci 2021;19:243-53. [PMID: 33888653 DOI: 10.9758/cpn.2021.19.2.243] [Reference Citation Analysis]
2 Jawad MY, Di Vincenzo JD, Ceban F, Jaberi S, Lui LMW, Gillissie ES, Alnafeesi Y, Rosenblat JD, McIntyre RS. The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis. Expert Opin Drug Saf 2022;:1-12. [PMID: 35387538 DOI: 10.1080/14740338.2022.2058488] [Reference Citation Analysis]
3 Fiorillo A, Carpiniello B, De Giorgi S, La Pia S, Maina G, Sampogna G, Spina E, Tortorella A, Vita A. Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review. Front Psychiatry 2018;9:493. [PMID: 30364225 DOI: 10.3389/fpsyt.2018.00493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
4 Oluboka OJ, Katzman MA, Habert J, McIntosh D, MacQueen GM, Milev RV, McIntyre RS, Blier P. Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient. Int J Neuropsychopharmacol 2018;21:128-44. [PMID: 29024974 DOI: 10.1093/ijnp/pyx081] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
5 Brietzke E, Mansur RB, McIntyre RS. Impact of inequalities in health care on the mortality risk of individuals with severe mental illnesses. Braz J Psychiatry 2017;39:193-4. [PMID: 28813113 DOI: 10.1590/1516-4446-2017-2391] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Di Nicola M, Pepe M, Panaccione I, Moccia L, Dattoli L, Molinaro M, Sani G, Janiri L, McIntyre RS. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis. CNS Spectr 2020;:1-9. [PMID: 32772956 DOI: 10.1017/S109285292000173X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Hung CI, Lin G, Chiang MH, Chiu CY. Metabolomics-based discrimination of patients with remitted depression from healthy controls using 1H-NMR spectroscopy. Sci Rep 2021;11:15608. [PMID: 34341439 DOI: 10.1038/s41598-021-95221-1] [Reference Citation Analysis]
8 Hossain R, Al-Khafaji K, Khan RA, Sarkar C, Islam MS, Dey D, Jain D, Faria F, Akbor R, Atolani O, Oliveira SMR, Siyadatpanah A, Pereira ML, Islam MT. Quercetin and/or Ascorbic Acid Modulatory Effect on Phenobarbital-Induced Sleeping Mice Possibly through GABAA and GABAB Receptor Interaction Pathway. Pharmaceuticals (Basel) 2021;14:721. [PMID: 34451819 DOI: 10.3390/ph14080721] [Reference Citation Analysis]
9 Potměšil P. What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice? Ther Adv Psychopharmacol 2019;9:2045125319855206. [PMID: 31312426 DOI: 10.1177/2045125319855206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wang G, Si TM, Li L, Fang Y, Wang CX, Wang LN, Tan KHX, Ettrup A, Eriksen HF, Luo S, Ge L. Cognitive symptoms in major depressive disorder: associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China. Neuropsychiatr Dis Treat 2019;15:1723-36. [PMID: 31308667 DOI: 10.2147/NDT.S195505] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Christensen MC, Wong CMJ, Baune BT. Symptoms of Major Depressive Disorder and Their Impact on Psychosocial Functioning in the Different Phases of the Disease: Do the Perspectives of Patients and Healthcare Providers Differ? Front Psychiatry 2020;11:280. [PMID: 32390877 DOI: 10.3389/fpsyt.2020.00280] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Cao B, Park C, Subramaniapillai M, Lee Y, Iacobucci M, Mansur RB, Zuckerman H, Phan L, McIntyre RS. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder. Front Psychiatry 2019;10:17. [PMID: 30766492 DOI: 10.3389/fpsyt.2019.00017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
13 Chokka P, Bougie J, Rampakakis E, Proulx J. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr 2019;24:338-47. [PMID: 29792585 DOI: 10.1017/S1092852918000913] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
14 Ebert B, Miskowiak K, Kloster M, Johansen J, Eckholm C, Wærner T, Holme M, Bruun LM. An ethnographic study of the effects of cognitive symptoms in patients with major depressive disorder: the IMPACT study. BMC Psychiatry 2017;17:370. [PMID: 29157207 DOI: 10.1186/s12888-017-1523-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]